Abstract: A surface electrode for patient monitoring includes a flexible substrate, a dry electrode on the substrate, and a wet electrode configured to contact an electrode gel in contact with a patient's skin. A conductive epoxy is arranged between the dry electrode and the wet electrode. The conductive epoxy is configured to protect the dry electrode from corrosion and transfer electrical potentials from the wet electrode to the printed dry electrode.

Abstract: An acoustic receiver includes a first receiver subassembly having a bottom housing plate with a motor assembly fastened thereto, and a second receiver subassembly having a closed-ended receiver housing sidewall fastened to the bottom housing plate that includes at least one sidewall opening where a portion of the acoustic receiver is disposed in the at least one sidewall opening.

Abstract: An acoustic receiver includes a first receiver subassembly having a bottom housing plate with a motor assembly fastened thereto, and a second receiver subassembly having a closed-ended receiver housing sidewall fastened to the bottom housing plate that includes at least one sidewall opening where a portion of the acoustic receiver is disposed in the at least one sidewall opening.

Abstract: In accordance with one aspect, a diaphragm for an acoustic receiver is provided that includes a frame, a paddle flexibly coupled to the frame, and a gap between a portion of the paddle and the frame. The diaphragm further includes siloxane material coupled to at least a portion of the paddle and to at least a portion of the frame. The siloxane material covers the gap. In another aspect, a method is provided for making an acoustic receiver diaphragm.

Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

Abstract: A non-invasive metering system enables on-demand, metered usage licensing of software applications. A packaging module generates a secure application package for an original, unmodified application authored by a software publisher. The software publisher need not directly modify the code of the original application. Rather, the packaging module includes, within the secure application package but separate from the code of the application itself, a shell application that controls runtime aspects of the application, such as metering of the application. The secure application package is made available to users wishing to use the application on a metered basis.

Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

Abstract: This invention provides methods of treatment of IL-1 mediated diseases comprising administering a pharmaceutically effective amount of a pharmaceutical agent selected from the group of sulfasalazine, a statin, a glucocorticoid agent, an inhibitor of p38 kinase, an anti-IL-6-receptor antibody, anakinra, an IL-1 monoclonal antibody, an inhibitor of JAK3 protein tyrosine kinase, a M-CSF monoclonal antibody or a humanized anti-CD20 monoclonal antibody and a benzamide inhibitor of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The methods of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Abstract: The invention relates to an optical sub-assembly package for use in receiver optical sub-assemblies or transmitter optical sub-assemblies in which the electrical connections between the transducer chip, e.g. photo-detector or light source, and the device printed circuit board is made by a single flexible circuit conductor extending through the wall of the package. The package is comprised of a housing and a stiffening plate, which encloses and end of the housing and forms a mechanical support for an end of the flexible circuit conductor.

Abstract: The invention provides non-human, genetically-modified mammals and genetically modified animals cells having a functionally disrupted P2×7 receptor gene. Also provided are methods for producing genetically modified mice in which one or both P2×7R alleles have been functionally inactivated.

Abstract: The present invention relates to GST-Omega-2 and methods of using this diarylsulfonylurea binding protein (DBP) as a therapeutic target for the identification of agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-18.

Abstract: Disclosed are methods for screening compounds to identify therapeutic candidates for modulating bone mass and/or bone mineral density, as well as methods for treating skeletal disorders characterized by decreased bone mass and/or bone mineral density. The methods are based upon the identification and use of agonists of the P2X7 receptor.

Abstract: The invention provides non-human, genetically-modified mammals and genetically modified animals cells having a functionally disrupted P2×7 receptor gene. Also provided are methods for producing genetically modified mice in which one or both P2×7R alleles have been functionally inactivated.

Abstract: The invention relates to compositions and methods for treating or preventing inflammation, including rheumatoid arthritis (RA). The method comprises administering to mammals in need thereof an effective amount of a composition containing an agent that inhibits IL-1/18 combination with a TNF inhibitor.